Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide
Abstract Hydroxycarbamide (HC) is used as a cytoreductive treatment in myeloproliferative neoplasms (MPN). Observational studies have raised the possibility that HC contributes to the development of secondary malignancies, including skin tumours in MPN patients. In this retrospective observational s...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-11-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.551 |
| _version_ | 1797666942732992512 |
|---|---|
| author | Abhinav Mathur Joakim Edman Livia Liang Neil W. Scott Henry G. Watson |
| author_facet | Abhinav Mathur Joakim Edman Livia Liang Neil W. Scott Henry G. Watson |
| author_sort | Abhinav Mathur |
| collection | DOAJ |
| description | Abstract Hydroxycarbamide (HC) is used as a cytoreductive treatment in myeloproliferative neoplasms (MPN). Observational studies have raised the possibility that HC contributes to the development of secondary malignancies, including skin tumours in MPN patients. In this retrospective observational study, we report a single‐centre experience of 324 HC‐treated MPN patients with long‐term follow‐up, compared to 47 MPN patients not on HC. Thirty‐three patients (10.2%) (HC) versus one patient (2.1%) (no HC) developed skin tumours during follow‐up (Hazard ratios [HR] 5.70, 95% confidence intervals 0.66–48.09, p = 0.112). However, male gender, age at MPN diagnosis, type of MPN (polycythaemia rubra vera) and previous history of skin cancer were prognostic variables associated with development of skin cancer. |
| first_indexed | 2024-03-11T20:06:58Z |
| format | Article |
| id | doaj.art-e227082c1857411d91eeb12e2888d670 |
| institution | Directory Open Access Journal |
| issn | 2688-6146 |
| language | English |
| last_indexed | 2024-03-11T20:06:58Z |
| publishDate | 2022-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj.art-e227082c1857411d91eeb12e2888d6702023-10-03T16:50:47ZengWileyeJHaem2688-61462022-11-01341305130910.1002/jha2.551Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamideAbhinav Mathur0Joakim Edman1Livia Liang2Neil W. Scott3Henry G. Watson4Department Haematology Aberdeen Royal Infirmary Foresterhill Health Campus Aberdeen UKSchool of Medicine Medical Sciences and Nutrition Aberdeen University Aberdeen UKNational University Health System National University Hospital Singapore SingaporeInstitute of Applied Health Sciences University of Aberdeen, Polwarth Building, Foresterhill Aberdeen UKDepartment Haematology Aberdeen Royal Infirmary Foresterhill Health Campus Aberdeen UKAbstract Hydroxycarbamide (HC) is used as a cytoreductive treatment in myeloproliferative neoplasms (MPN). Observational studies have raised the possibility that HC contributes to the development of secondary malignancies, including skin tumours in MPN patients. In this retrospective observational study, we report a single‐centre experience of 324 HC‐treated MPN patients with long‐term follow‐up, compared to 47 MPN patients not on HC. Thirty‐three patients (10.2%) (HC) versus one patient (2.1%) (no HC) developed skin tumours during follow‐up (Hazard ratios [HR] 5.70, 95% confidence intervals 0.66–48.09, p = 0.112). However, male gender, age at MPN diagnosis, type of MPN (polycythaemia rubra vera) and previous history of skin cancer were prognostic variables associated with development of skin cancer.https://doi.org/10.1002/jha2.551essential thrombocythaemiahydroxycarbamidemelanomamyeloproliferative neoplasmnon‐melanoma skin cancerpolycythaemia vera |
| spellingShingle | Abhinav Mathur Joakim Edman Livia Liang Neil W. Scott Henry G. Watson Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide eJHaem essential thrombocythaemia hydroxycarbamide melanoma myeloproliferative neoplasm non‐melanoma skin cancer polycythaemia vera |
| title | Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide |
| title_full | Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide |
| title_fullStr | Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide |
| title_full_unstemmed | Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide |
| title_short | Skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide |
| title_sort | skin cancer in essential thrombocythaemia and polycythaemia vera patients treated with hydroxycarbamide |
| topic | essential thrombocythaemia hydroxycarbamide melanoma myeloproliferative neoplasm non‐melanoma skin cancer polycythaemia vera |
| url | https://doi.org/10.1002/jha2.551 |
| work_keys_str_mv | AT abhinavmathur skincancerinessentialthrombocythaemiaandpolycythaemiaverapatientstreatedwithhydroxycarbamide AT joakimedman skincancerinessentialthrombocythaemiaandpolycythaemiaverapatientstreatedwithhydroxycarbamide AT livialiang skincancerinessentialthrombocythaemiaandpolycythaemiaverapatientstreatedwithhydroxycarbamide AT neilwscott skincancerinessentialthrombocythaemiaandpolycythaemiaverapatientstreatedwithhydroxycarbamide AT henrygwatson skincancerinessentialthrombocythaemiaandpolycythaemiaverapatientstreatedwithhydroxycarbamide |